CC BY
0J, J . Дата отчета 2/14/2024
pu StrikePlagiarism com = " ЖИЖ Hr^H
_ Дата редактирования ---
Метаданные
Название
Амангелди Д без литер.docx
Автор Научный руководитель / Эксперт
Амангелди Д Амангелди Д
Подразделение
Kazakhstan's Medical University "KSPH"
Тревога
В этом разделе вы найдете информацию, касающуюся текстовых искажений. Эти искажения в тексте могут говорить о ВОЗМОЖНЫХ манипуляциях в тексте. Искажения в тексте могут носить преднамеренный характер, но чаще, характер технических ошибок при конвертации документа и его сохранении, поэтому мы рекоммендуем вам подходить к анализу этого модуля со всей долей ответственности. В случае возникновения вопросов, просим обращаться в нашу службу поддержки.
Замена букв
li
0
Интервалы AD 0
Микропробелы Q 0
Белые знаки 0
Парафразы (SmartMarks) a 22
Объем найденных подобий
КП-ия определяют, какой процент текста по отношению к общему объему текста был найден в различных источниках.. Обратите внимание!Высокие значения коэффициентов не означают плагиат. Отчет должен быть проанализирован экспертом.
КЦ
25
Длина фразы для коэффициента подобия 2
Поиск контента ИИ
1382
Количество слов
9428
Количество символов
Интегрированный модуль поиска контента А1. Нажмите «Подробнее», чтобы узнать больше о результатах и алгоритме поиска. Коэффициент вероятности ИИ
Подобия по списку источников
Ниже представлен список источников. В этом списке представлены источники из различных баз данных. Цвет текста означает в каком источнике он был найден. Эти источники и значения Коэффициента Подобия не отражают прямого плагиата. Необходимо открыть каждый источник и проанализировать сожержание и правильность оформления источника.
10 самых длинных фраз Цвет текста
ПОРЯДКОВЫЙ НОМЕР НАЗВАНИЕ И АДРЕС ИСТОЧНИКА URL (НАЗВАНИЕ БАЗЫ] КОЛИЧЕСТВО ИДЕНТИЧНЫХ СЛОВ (ФРАГМЕНТОВ]
1 http://pure-oai.bham.ac.uk/ws/files/94989127/1 s2.0 S1931524420300311 main.pdf 27 1.95 %
2 http://pure-oai.bham.ac.uk/ws/files/94989127/1 s2.0 S1931524420300311 main.pdf 27 1.95 %
3 РЕЗИСТЕНТНОСТЬ ГОНОРЕИ К АНТИМИКРОБНЫМ ПРЕПАРАТАМ В УСЛОВИЯХ КРУПНОГО ГОРОДА 5/22/2023 Kazakhstan's Medical University "KSPH" (Kazakhstan's Medical University "KSPH") 25 1.81 %
4 https://pressbooks.uwf.edu/medicalterminoloav/chapter/male-reproductive-svstem/ 14 1.01 %
5 http://pure-oai.bham.ac.uk/ws/files/94989127/1 s2.0 S1931524420300311 main.pdf 13 0.94 %
6 Racial Variation in Toll-like Receptor Variants Among Women With Pelvic Inflammatory Disease N. S. Mahmood; 11 0.80 %
7 http://pure-oai.bham.ac.Uk/ws/files/94989127/1 s2.0 S1931524420300311 main.pdf 9 0.65 %
8 https://www.ncbi.nlm.nih.aov/pmc/articles/PMC9505656/ 9 0.65 %
9 https://www.bustle.com/p/measles-lona-term-effects-include-immunitv-weakenina-studies-show-19288829 7 0.51 %
10 Antimicrobial resistance and molecular epidemiology using whole-genome sequencing of <em class='a-plus-plus'>Neisseria gonorrhoeae</em> in Ireland, 2014-2016: focus on extended-spectrum cephalosporins and azithromycin P. Walsh, M. Unemo, M. Mac Aogain, B. Crowley,L. Ryan, L. Rose, B. Lawlor, N. Fennelly, D. Golparian; 7 0.51 %
из базы данных RefBooks (3.33 %) ■
ПОРЯДКОВЫЙ НОМЕР НАЗВАНИЕ КОЛИЧЕСТВО ИДЕНТИЧНЫХ СЛОВ (ФРАГМЕНТОВ)
Источник: Paperity - abstrakty
1 Antimicrobial resistance and molecular epidemiology using whole-genome sequencing of <em class='a-plus-plus'>Neisseria gonorrhoeae</em> in Ireland, 2014-2016: focus on extended-spectrum cephalosporins and azithromycin P. Walsh, M. Unemo, M. Mac Aogain, B. Crowley,L. Ryan, L. Rose, B. Lawlor, N. Fennelly, D. Golparian; 13 (2) 0.94 %
2 Half the world's population are exposed to increasing air pollution G. Shaddick, P. Mudu, S. Gumy, M. L. Thomas, G. Ruggeri; 5 (1) 0.36 %
Источник: Paperity
1 Racial Variation in Toll-like Receptor Variants Among Women With Pelvic Inflammatory Disease N. S. Mahmood; 11 (1) 0.80 %
2 Linezolid to Decrease Length of Stay in the Hospital for Patients with Methicillin-Resistant Staphylococcus aureus Infection L. Bugge; 6 (1) 0.43 %
3 A multicentre double-blind randomised controlled trial evaluating the efficacy of daily use of antibacterial mouthwash against oropharyngeal gonorrhoea among men who have sex with men: the OMEGA (Oral Mouthwash use to Eradicate GonorrhoeA) study protocol Andrew E. Grulich, Benjamin P. Howden, Jane S. Hocking, David M. Whiley, Sandra Walker, Norman Roth, Lei Zhang, Christopher K. Fairley, Basil Donovan, Tim R. H. Read, Matthew G. Law, David J. Templeton,Eric P. F. Chow, Samuel Phillips, Marcus Y. Chen, Anna M. McNulty, Catriona S. Bradshaw, Sepehr N. Tabrizi, Kate Maddaford, Richard Moore, David A. Lewis, John M. Kaldor, Vincent J. Cornelisse; 6 (1) 0.43 %
4 Tuberculosis in prisons in sub-Saharan Africa: a potential time bomb Alimuddin Zumla, Nathan Kapata,Justin O'Grady, Matthew Bates, Peter Mwaba; 5 (1) 0.36 %
из домашней базы данных (1.81 %) ■
ПОРЯДКОВЫЙ КОЛИЧЕСТВО ИДЕНТИЧНЫХ СЛОВ
НОМЕР НАЗВАНИЕ (ФРАГМЕНТОВ]
1 РЕЗИСТЕНТНОСТЬ ГОНОРЕИ К АНТИМИКРОБНЫМ ПРЕПАРАТАМ В УСЛОВИЯХ 25 (1) 1.81 %
КРУПНОГО ГОРОДА
5/22/2023
Kazakhstan's Medical University "KSPH" (Kazakhstan's Medical University "KSPH")
из программы обмена базами данных (0.00 %) ■
ПОРЯДКОВЫЙ НОМЕР НАЗВАНИЕ КОЛИЧЕСТВО ИДЕНТИЧНЫХ СЛОВ (ФРАГМЕНТОВ]
из интернета (9.33 %) ■
ПОРЯДКОВЫЙ НОМЕР ИСТОЧНИК URL КОЛИЧЕСТВО ИДЕНТИЧНЫХ СЛОВ (ФРАГМЕНТОВ]
1 httD://Dure-oai.bham.ac.uk/ws/files/94989127/1 s2.0 S1931524420300311 main.Ddf 76 (4) 5.50 %
2 https://pressbooks.uwf.edu/medicalterminoloav/chapter/male-reproductive-svstem/ 20 (2) 1.45 %
3 https://www.ncbi.nlm.nih.aov/pmc/articles/PMC9505656/ 15 (2) 1.09 %
4 https://www.bustle.com/p/measles-lona-term-effects-include-immunitv-weakenina-studies-show-19288829 7 (1) 0.51 %
5 https://www.mavoclinic.ora/diseases-conditions/aonorrhea/svmptoms-causes/svc-20351774 6 (1) 0.43 %
6 https://en.wikipedia.ora/wiki/Gonorrhea 5 (1) 0.36 %
Список принятых фрагментов (нет принятых фрагментов)
ПОРЯДКОВЫЙ НОМЕР СОДЕРЖАНИЕ КОЛИЧЕСТВО ИДЕНТИЧНЫХ СЛОВ (ФРАГМЕНТОВ]
THE DANGER OF ANTIBIOTIC RESISTANCE OF NEISSERIA GONORRHOEAE WORLDWIDE *D.M. Amangeldy, A.T. Dzhumabekov, B.A. Zhumabekova Kazakhstan medical University "KSPH", Almaty, Kazakhstan Abstract
Gonorrhea is a sexually transmitted infection caused by the bacterium Neisseria gonorrhoeae. According to the WHO, the number of new cases of sexually transmitted diseases in 2020 reached 374 million, a quarter of which were caused by gonorrhea - 82.4 million, a 5.64% increase compared to 2012 when there were 78 million new cases.
Introduction. Gonorrhea remains one of the most common sexually transmitted infections worldwide [1], the causative agent of which is _ the gram-negative bacteria Neisseria gonorrhoeae.
Currently, gonorrhea poses a significant threat to public health due to the rapid increase in the incidence and resistance of the microorganism to antibiotics [2].
More than 78 million cases are reported worldwide each year, and treatment options are limited in low-income countries and marginalized groups in richer countries [3]. Gonorrhea continues to pose serious global ublic health: the World Health Organization
(WHO) estimates that 78.31 million new cases the disease were ortec in 2008 among people aged 15 to 49 years. According to the Centers for Disease Control and Prevention (CDC), gonorrhea is the second most common bacterial disease n the United States [4]. In 2015, about 395,200 cases of gonorrhea were reported, which is 27% more than in 2012.
Incidence is higher in resource-limited countries-for example, incidence is 50 cases per 1,000 men and 42 cases per 1,000 women in
sub-Saharan Africa, compared with 9 cases per 1,000 men and 6 cases per 1,000 women in North America and Europe [5]. In the
United States, incidence in 2018 was 600000 cases - an increase of more than 80% over the historical low in 2009. The United Kingdom has
similar numbers (up 26% in 2018 from 2017 and at its highest level since 1978) and Australia (up 63% in 5 years) [5-7].
The increase is due to the spread among young men and men who have sex with men [8-9]. N. gonorrhoeae infects and leads to
inflammation in various mucosal tissues including the cervix, urethra, rectum, pharynx, and conjunctiva and subsequently can
lead to the spread to other locations [10]. Urethral infection is the most common and often leads to discharge and dysuria. In women,
cervical infection is often asymptomatic [11]. N. gonorrhoeae can progress to pelvic inflammatory disease (PID) [12], what can lead
to infertility, chronic pelvic pain and ectopic _ - consequences affect a significant proportion of women infected (18%, 29%
and 0.6% respectively) [13] with the worst consequences being delayed care and repeated episodes of PID.
Key words: neisseria gonorrhoeae, cephalosporins (ESCs), The Gonococcal Isolate Surveillance Project (GISP).
Objectives
To evaluate worldwide tendency spreading of Neisseria gonorrhoeae resistant strains in 21 century based scientific publications. Materials and methods
We have conducted a literature review from 2014-2021 of incidence Neisseria gonorrhoeae antibiotic resistant strains, ant trends of possible changes in future. Current stability position
As predicted by the U.S. Centers for Disease Control and Prevention [12] in 2012, N. gonorrhoeae has become a superinfection and is an urgent public health threat.
Increasingly, gonococcal strains resistant to extended-spectrum cephalosporins (ESCs) and azithromycin are being identified, which can lead to a situation where gonorrhea is not treatable. In fact, strains of N. Gonorrhoeae H041 (MIC of ceftriaxone 2 mg/L), F89 (MIC of ceftriaxone 1 mg/L), and A8806 (MIC of ceftriaxone 0.5 mg/L) with high levels of ceftriaxone resistance have been isolated from patients in Japan [13], France [14] and Australia [15], respectively. Moreover, a new ceftriaxone- and multidrug-resistant N. gonorrhoeae was recently isolated in Japan [16]. At the same time, another study in Canada [17] showed that the proportion of isolates with reduced sensitivity to cephalosporins decreased significantly between 2011 and 2014, while resistance to azithromycin increased significantly during the same period. This study concluded that continued monitoring of gonococcal antimicrobial susceptibility is necessary for the relevance of treatment recommendations to slow the spread of isolates with decreased sensitivity to cephalosporins and resistance to azithromycin. Also, the first case of failure of standard dual antimicrobial treatment for gonorrhea was recently reported in the United Kingdom [18]. Results of AMP sensitivity tests showed that the strain was resistant to ceftriaxone, azithromycin, cefixime, cefotaxime, penicillin, tetracycline, and ciprofloxacin, but sensitivity to spectinomycin was present. As these reports show, the treatment of gonococcal infection is in serious jeopardy because of the emergence of antimicrobial resistance.
With this in mind, governments around the world have created data collection programs to study how this bacterium develops resistance and manifests itself at the community level [19]. The three most common programs are the Gonococcal Resistance to Antimicrobial Resistance Surveillance Program (GRASP) in the United Kingdom ("httpsV/www.govuk/government/publications/gonococcal-resistance-to-antimicrobialssurveillance-program-grasp-report), the Gonococcal Surveillance Project (GISP) in the United States (https://www.cdc.gov/std/gisp/), and the European Gonococcal Resistance Surveillance Program (Euro-GASP)
("http://ecdc.europa.eu/en/healthtopics/aonorrhoea/response-plan/pages/strengthenina-antimicrobialsurveillance.aspx"). All three programs have a common goal: to identify the emergence of any AMRs that might threaten the efficacy of existing first-line treatments. Reports from all three programs provide insight into how antibiotic resistance develops among strains of N. Gonorrhoeae [20].
Figure 1. - Gonococcal Antimicrobial Resistance Surveillance Program (GRASP) in the United Kingdom 2016-2020 year
Figure 2. - The Gonococcal Isolate Surveillance Project (GISP) in United States of America
Figure 3. - European Gonococcal Resistance Surveillance Program (Euro-GASP) 2009-2016
As can be seen from these graphs, different treatment policies between the United Kingdom, the United States, and the European Union have led to different trends in antibiotic resistance. For example, GRASP(UK) reports a decrease in penicillin resistance from 2007 to 2011, followed by an upward trend reaching 22.6% in 2014. Similarly, GISP(USA) also reports a steady upward trend in penicillin resistance, which has more than doubled in the last ten years (from 16% in 2004 to 3 8% in 2014). On the other hand, Euro-GASP (European Union) shows a stable level of penicillin resistance at 13-14% since 2004. As for ceftriaxone, all three reports had resistance rates close to 0%. GRASP(UK) and Euro-GASP(EU) detected a peak of cefixime resistance in 2011 and 2010, respectively, after which the resistance rate dropped significantly in both cases (from 11 to 1.4% for GRASP(UK) and 9-2% for Euro-GASP). The detection of ciprofloxacin-resistant strains has increased in GRASP since 2012 (25 to 37.3% in 2014) and in GISP since 2009 (12 to 21% in 2014). On the other hand, Euro-GASP reports show a decrease in ciprofloxacin resistance from 63% in 2009 to 50% in 2014. Finally, resistance to azithromycin varies considerably among reports. GRASP shows azithromycin resistance rates below 2% since 2007, while GISP and Euro-GASP show an increase in resistant strains in 2014 (from 1 to 4% in GISP and from 5.4% to 7.9% in Euro-GASP).
Conclusion
Based on the red flags around the world, we have to assume that the superinfection of Neisseria gonorrhoeae is making world wary. Following this trend, resistant strains will soon appear more and more often in other countries as well. There monitoring of strain prevalence at the regional level of each country and for global cohesion in reporting changes.
ОПАСНОСТЬ УСТОЙЧИВОСТИ NEISSERIA GONORRHOEAE К АНТИБИОТИКАМ ВО ВСЕМ МИРЕ *Д.М. Амангельды, А.Т. Джумабеков, Б.А. Жумабекова Казахстанский медицинский университет "ВШОЗ", Алматы, Казахстан Аннотация
Гонорея - это инфекция, передающаяся половым путем, вызываемая бактерией Neisseria gonorrhoeae. По данным ВОЗ, число новых случаев заболеваний, передающихся половым путем, в 2020 году достигло 374 миллионов, четверть из которых были вызваны гонореей - 82,4 миллиона, что на 5,64% больше по сравнению с 2012 годом, когда было зарегистрировано 78 миллионов новых случаев.
Ключевые слова: neisseria gonorrhoeae, цефалоспорины, Проект по эпиднадзору за изолятами гонококка.
NEISSERIA GONORRHOEAE-ДЩ БYКIЛ ЭЛЕМДЕП АНТИБИОТИКТЕРГЕ Т0З1МД1Л1К КАУП1
*Д.М. Амангелду А.Т. Жумабеков, Б.Э. Жумабекова
"КДСЖМ" Казахстан медициналык университету Алматы, Казахстан
Тушндеме
Гонорея - Neisseria gonorrhoeae бактериясы тудыратын жыныстык жолмен бертелн инфекция. ДД¥ мэлiметтерi бойынша, жыныстык жолмен бертетш аурулардьщ жаца жагдайлары 2020 жылы 374 миллионга жетп, оньщ терттен бiр белт гонореядан 82,4 миллионга
scientists around the is a need for closer
жетп, бул 2012 жылмен салыстырганда 5,64% - га есп, бул кезде 78 миллион жаца жагдай ■пркелдг ТYЙiн сездер: neisseria aonorrhoeae, цефалоспориндер, гонококк изоляттарын кадагалау жобасы.
